A Beginner’s Guide to Immunotherapy: What to Expect from Your First Course

Recent Trends in Immunotherapy

Immunotherapy has moved from experimental to a standard-of-care option for several cancer types in recent years. Clinicians increasingly combine checkpoint inhibitors with targeted drugs or chemotherapy to improve response rates. The field now sees a rapid expansion of clinical trials exploring neoadjuvant (pre-surgery) and adjuvant (post-surgery) immunotherapy regimens, as well as new approaches like bispecific antibodies and oncolytic viruses.

Background: How Immunotherapy Differs from Traditional Treatments

Unlike chemotherapy or radiation, immunotherapy aims to harness the patient’s own immune system to recognize and attack cancer cells. The first course typically involves intravenous infusion of a checkpoint inhibitor (e.g., anti-PD-1 or anti-CTLA-4 agents) given over 30–90 minutes. Treatment is usually administered once every two to six weeks in a hospital or infusion center. Patients may receive a pre‑medication regimen (antihistamines, acetaminophen) to reduce infusion reactions.

• Cycle structure: One “course” often consists of four to six cycles (3–6 months), with response assessed via imaging every two to three cycles.
• Monitoring: Blood tests (CBC, liver/kidney function, thyroid panel) are performed before each infusion to detect early immune-related adverse events.
• Duration: Treatment may continue for up to two years if tolerated and if the disease does not progress.

User Concerns: What Patients and Caregivers Ask

Patients starting their first course commonly worry about side effects and effectiveness. Immunotherapy side effects differ from chemotherapy — they stem from overactivation of the immune system rather than direct cell kill. Most are mild to moderate and manageable with supportive care.

• Common side effects: Fatigue, rash, diarrhea, joint pain, and infusion reactions (fever, chills).
• Immune-related adverse events (irAEs): Can affect the skin, gut, liver, lungs, or endocrine glands. Early recognition and treatment (corticosteroids, hormone replacement) are key.
• Efficacy expectations: Response rates vary widely — from 15–40% in solid tumors (e.g., lung, melanoma, kidney) to higher rates in certain blood cancers. Many patients benefit from a “pseudoprogression” where tumors appear to enlarge before shrinking.
• Cost and access: Insurance pre‑authorization is often required; patient assistance programs exist for eligible individuals.

Likely Impact: Shifting the Treatment Landscape

For many patients, immunotherapy offers a durable response that can last years after completing the first course, especially when a complete response is achieved. However, not all tumors respond — “cold” tumors (with low immune infiltration) often require combination approaches. The growing use of biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability helps identify those most likely to benefit.

Outlook: Immunotherapy is rarely curative as a single agent, but its integration into early‑line protocols has significantly improved survival in advanced melanoma and non‑small cell lung cancer. The impact is also being studied in earlier‑stage disease to reduce recurrence.

What to Watch Next

• Personalized cancer vaccines: mRNA and peptide vaccines tailored to individual tumor mutations are entering late‑stage trials and may become part of the first‑course regimen.
• CAR‑T cell therapy in solid tumors: Expanding beyond blood cancers could broaden the reach of immunotherapy courses.
• Biomarker‑driven de‑escalation: Research into stopping immunotherapy early in patients with a deep response may reduce unnecessary exposure.
• Oral immunotherapies: Checkpoint inhibitors in pill form are under development, potentially simplifying treatment administration.